Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Biomea Fusion, Inc.

Biomea Fusion to Host Conference Call and Webcast to Discuss Initial Phase II Clinical Data for BMF-219 in Subjects with Type 2 Diabetes on March 28th, 2023 at 8:30 a.m. ET
From Biomea Fusion, Inc.
Via Globe NewsWire
Tickers BMEA
Biomea Fusion To Participate In Upcoming Investor Events
From Biomea Fusion, Inc.
Via Globe NewsWire
Tickers BMEA
Biomea Fusion Doses First Patient in Phase I/Ib Clinical Trial (COVALENT-102) of BMF-219 in KRAS Mutant Solid Tumors
From Biomea Fusion, Inc.
Via Globe NewsWire
Tickers BMEA
Biomea Fusion to Present at 41st Annual J.P. Morgan Healthcare Conference and Highlight 2023 Corporate Milestones
From Biomea Fusion, Inc.
Via Globe NewsWire
Tickers BMEA
Biomea Fusion Announces Dosing of First Patient with Type 2 Diabetes in the United States in Ongoing Phase I/II (COVALENT-111) Study of BMF-219
From Biomea Fusion, Inc.
Via Globe NewsWire
Tickers BMEA
Biomea Fusion Announces FDA Clearance of Investigational New Drug (IND) Application for Covalent Menin Inhibitor BMF-219 in Type 2 Diabetes
From Biomea Fusion, Inc.
Via Globe NewsWire
Tickers BMEA
Biomea Fusion Presents at the 2022 ASH Annual Meeting Preclinical Data on BMF-500 Supporting its Potential as the Most Potent and Selective FLT3 Inhibitor to Date
From Biomea Fusion, Inc.
Via Globe NewsWire
Tickers BMEA
Biomea Fusion to Participate in Piper Sandler 34th Annual Healthcare Conference
From Biomea Fusion, Inc.
Via Globe NewsWire
Tickers BMEA
Biomea Fusion Reports Third Quarter 2022 Financial Results and Business Highlights
From Biomea Fusion, Inc.
Via Globe NewsWire
Tickers BMEA
Biomea Fusion to Present Preclinical Data for BMF-500, an Investigational Oral Covalent FLT3 Inhibitor, at the 64th American Society of Hematology (ASH) Annual Meeting
From Biomea Fusion, Inc.
Via Globe NewsWire
Tickers BMEA
Biomea Fusion Announces Dosing of First Patient with Type 2 Diabetes and Completion of Phase I Healthy Volunteer Portion of Phase I/II (COVALENT-111) Study of BMF-219
From Biomea Fusion, Inc.
Via Globe NewsWire
Tickers BMEA
Biomea Fusion Announces First Patient Dosed with Chronic Lymphocytic Leukemia (CLL) in COVALENT-101 Trial
From Biomea Fusion, Inc.
Via Globe NewsWire
Tickers BMEA
BMF-219 Enters the Clinic for KRAS Solid Tumors
From Biomea Fusion, Inc.
Via Globe NewsWire
Tickers BMEA
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.